CyFlow™ CD8a Low Endotoxin
| Alternative Name: | Leu2, T8 |
| Antibody: | Yes |
| Antigen: | CD8a |
| Application: | Flow cytometry, Functional assays, Immunocytochemistry, Immunohistochemistry, Immunoprecipitation |
| Clonality: | monoclonal |
| Clone: | 53-6.7 |
| Field of Interest: | Immunophenotyping, MHC |
| Format/Fluorochrome: | Low Endotoxin |
| Isotype: | IgG2a |
| Regulatory Status: | RUO |
| Source Species: | Rat |
| Target Species: | Mouse |
| Product number: | AN289615 |
For Research Use Only
| Concentration Unit | mg/mL |
| Concentration | 1 |
| Quantity | 0.1 mg |
| Volume | 0.1 mL |
| Immunogen | Mouse spleen cells |
| Background Information | CD8a (CD8 α) subunit of CD8 T cell coreceptor is expressed in CD8 α/β heterodimers on majority of MHC I-restricted conventional T cells and thymocytes and in CD8 α/α homodimers on subsets of memory T cells, intraepithelial lymphocytes, NK cells, macrophages and dendritic cells. Regulation of CD8 β level on T cell surface seems to be an important mechanism to control their effector function. Assembly of CD8 α/β but not α/α dimers is connected with formation or localization to the lipid rafts. Recruiting triggered TCR complexes to these membrane microdomains as well as affinity of TCR to MHC I is modulated by CD8, thereby affecting the functional diversity of the TCR signaling. |
| Storage Buffer | The reagent is provided in azide-free phosphate buffered saline (PBS) solution, pH ≈7.4; 0.2 µm filter sterilized. Endotoxin level is less than 0.01 EU/µg of the protein, as determined by the LAL test. |
| Storage | Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze. |
| Stability | Do not use after expiration date stamped on vial label. |
| Ledbetter JA, Herzenberg LA: Xenogeneic monoclonal antibodies to mouse lymphoid differentiation antigens. Immunol Rev. 1979; 47:63‑90. < PMID: 398327 > | Ledbetter JA, Rouse RV, Micklem HS, Herzenberg LA: T cell subsets defined by expression of Lyt‑1,2,3 and Thy‑1 antigens: Two‑parameter immunofluorescence and cytotoxicity analysis with monoclonal antibodies modifies current views. J Exp Med. 1980 Aug 1; 152(2):280‑95. < PMID: 6156984 > | Takahashi K, Nakata M, Tanaka T, Adachi H, Nakauchi H, Yagita H, Okumura K: CD4 and CD8 regulate interleukin 2 responses of T cells. Proc Natl Acad Sci USA. 1992 Jun 15; 89(12):5557‑61. < PMID: 1608966 > | Grabbe S, Varga G, Beissert S, Steinert M, Pendl G, Seeliger S, Bloch W, Peters T, Schwarz T, Sunderkötter C, Scharffetter-Kochanek K: Beta2 integrins are required for skin homing of primed T cells but not for priming naive T cells. J Clin Invest. 2002 Jan; 109(2):183‑92. < PMID: 11805130 > | Hata H, Sakaguchi N, Yoshitomi H, Iwakura Y, Sekikawa K, Azuma Y, Kanai C, Moriizumi E, Nomura T, Nakamura T, Sakaguchi S: Distinct contribution of IL‑6, TNF‑alpha, IL‑1, and IL‑10 to T cell‑mediated spontaneous autoimmune arthritis in mice. J Clin Invest. 2004 Aug; 114(4):582‑8. < PMID: 15314695 > | Ko SY, Ko HJ, Chang WS, Park SH, Kweon MN, Kang CY: alpha‑Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor. J Immunol. 2005 Sep 1; 175(5):3309‑17. < PMID: 16116223 > | Bouwer HG, Alberti-Segui C, Montfort MJ, Berkowitz ND, Higgins DE: Directed antigen delivery as a vaccine strategy for an intracellular bacterialpathogen. Proc Natl Acad Sci USA. 2006 Mar 28; 103(13):5102‑7. < PMID: 16549792 > | Kamimura D, Sawa Y, Sato M, Agung E, Hirano T, Murakami M: IL‑2 in vivo activities and antitumor efficacy enhanced by an anti‑IL‑2 mAb. J Immunol. 2006 Jul 1; 177(1):306‑14. < PMID: 16785526 > | Mochimaru H, Usui T, Yaguchi T, Nagahama Y, Hasegawa G, Usui Y, Shimmura S, Tsubota K, Amano S, Kawakami Y, Ishida S: Suppression of alkali burn‑induced corneal neovascularization by dendritic cell vaccination targeting VEGF receptor 2. Invest Ophthalmol Vis Sci. 2008 May; 49(5):2172‑7. < PMID: 18263815 >